McCloskey Scott Marshall, McMullin Mary Frances, Walker Brian, Irvine Alexandra E
CCRCB, Queen's University of Belfast, Belfast, Northern Ireland.
Hematol Oncol. 2008 Jun;26(2):73-81. doi: 10.1002/hon.848.
Many cellular processes converge on the proteasome, and its key regulatory role is increasingly being recognized. Proteasome inhibition allows the manipulation of many cellular pathways including apoptotic and cell cycle mechanisms. The proteasome inhibitor bortezomib has enhanced responses in newly diagnosed patients with myeloma and provides a new line of therapy in relapsed and refractory patients. Malignant cells are more sensitive to proteasome inhibition than normal haematopoietic cells. Proteasome inhibition enhances many conventional therapies and its role in leukaemia is promising.
许多细胞过程都汇聚于蛋白酶体，其关键的调节作用日益得到认可。蛋白酶体抑制可调控包括凋亡和细胞周期机制在内的多种细胞途径。蛋白酶体抑制剂硼替佐米增强了新诊断骨髓瘤患者的反应，并为复发和难治性患者提供了新的治疗方法。恶性细胞比正常造血细胞对蛋白酶体抑制更敏感。蛋白酶体抑制增强了许多传统疗法，其在白血病治疗中的作用前景广阔。
